Possible prognostic and therapeutic significance of c-kit expression, mast cell count and microvessel density in renal cell carcinoma

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 13060-13076

  Marech, Ilaria ^a   Gadaleta, Cosmo Damiano ^a   Ranieri, Girolamo ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

c Kit receptor; Mast cells; Microvessel density; Molecular targeting agents; Renal cell carcinoma; Stem cell factor

Indexed keywords

CULLIN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN SHC; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; STAT3 PROTEIN; STEM CELL FACTOR; STRESS ACTIVATED PROTEIN KINASE; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ANGIOGENESIS; ANGIOMYOLIPOMA; ATYPICAL CHRONIC MYELOID LEUKEMIA; CAPILLARY DENSITY; CARCINOGENESIS; CELL COUNT; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE FREE SURVIVAL; DNA MICROARRAY; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAST CELL; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; CARCINOMA, RENAL CELL; CYTOLOGY; KIDNEY NEOPLASMS; METABOLISM; MICROVASCULATURE; PATHOPHYSIOLOGY; PROGNOSIS;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MAST CELLS; MICROVESSELS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; STEM CELL FACTOR;

EID: 84905009826     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150713060     Document Type: Review

References (79)

1. Ridge, C.A.; Pua, B.B.; Madoff, D.C. Epidemiology and staging of renal cell carcinoma. Semin. Interv. Radiol. 2014, 31, 3-8.
2. Ljungberg, B.; Campbell, S.C.; Cho, H.Y.; Jacqmin, D.; Lee, J.E.; Weikert, S.; Kiemeney, L.A. The epidemiology of renal cell carcinoma. Eur. Urol. 2011, 60, 615-621.
3. Srigley, J.R.; Delahunt, B.; Eble, J.N.; Egevad, L.; Epstein, J.I.; Grignon, D.; Hes, O.; Moch, H.; Montironi, R.; Tickoo, S.K., et al. The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia. Am. J. Surg. Pathol. 2013, 37, 1469-1489.
4. Vanharanta, S.; Shu, W.; Brenet, F.; Hakimi, A.A.; Heguy, A.; Viale, A.; Reuter, V.E.; Hsieh, J.J.; Scandura, J.M.; Massagué, J. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat. Med. 2013, 19, 50-56.
5. Shen, C.; Kaelin, W.G., Jr. The VHL-HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. 2013, 23, 18-25.
6. Zhang, Q.; Yang, H. The roles of VHL-dependent ubiquitination in signaling and cancer. Front. Oncol. 2012, 2, 35.
7. Medina Villaamil, V.; Aparicio Gallego, G.; Santamarina Caínzos, I.; Valladares-Ayerbes, M.; Antón Aparicio, L.M. Searching for HIF1-α interacting proteins in renal cell carcinoma. Clin. Transl. Oncol. 2012, 14, 698-708.
8. Billemont, B.; Méric, J.B.; Izzedine, H.; Taillade, L.; Sultan-Amar, V.; Rixe, O. Angiogenesis and renal cell carcinoma. Bull. Cancer 2007, 94, S232-S240.
9. Horstmann, M.; Hennenlotter, J.; Geiger, L.M.; Vogel, U.; Schmid, H.; Kuehs, U.; Stenzl, A.; Bedke, J. Evaluation of the Kit/stem cell factor axis in renal tumours. Anticancer Res. 2012, 32, 4339-4345.
10. Reith, A.D.; Ellis, C.; Lyman, S.D.; Anderson, D.M.; Williams, D.E.; Bernstein, A.; Pawson, T. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J. 1991, 10, 2451-2459.
11. Cools, J.; de Angelo, D.J.; Gotlib, J.; Stover, E.H.; Legare, R.D.; Cortes, J.; Kutok, J.; Clark, J.; Galinsky, I.; Griffin, J.D., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003, 348, 1201-1214.
12. Ranieri, G. Hot topic: Targeting tumor angiogenesis: An update. Curr. Med. Chem. 2012, 19, 937.
13. Ribatti, D.; Ranieri, G.; Basile, A.; Azzariti, A.; Paradiso, A.; Vacca, A. Tumor endothelial markers as a target in cancer. Expert Opin. Ther. Targets 2012, 16, 1215-1225.
14. Broudy, V.C. Stem cell factor and hematopoiesis. Blood 1997, 90, 1345-1364.
15. Nick, H.J.; Kim, H.G.; Chang, C.W.; Harris, K.W.; Reddy, V.; Klug, C.A. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia. Blood 2012, 119, 1522-1531.
16. London, C.A.; Galli, S.J.; Yuuki, T.; Hu, Z.Q.; Helfand, S.C.; Geissler, E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-Kit. Exp. Hematol. 1999, 27, 689-697.
17. Broudy, V.C.; Lin, N.L.; Sabath, D.F. The fifth immunoglobulin-like domain of the kit receptor is required for proteolytic cleavage from the cell surface. Cytokine 2001, 15, 188-195.
18. López-Martin, A.; Ballestín, C.; Garcia-Carbonero, R.; Castaño, A.; Lopez-Ríos, F.; López-Encuentra, A.; Sánchez-Cespedes, M.; Castellano, D.; Bartolomé, A.; Cortés-Funes, H., et al. Prognostic value of Kit expression in small cell lung cancer. Lung Cancer 2007, 56, 405-413.
19. Chau, W.K.; Ip, C.K.; Mak, A.S.; Lai, H.C.; Wong, A.S. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling. Oncogene 2013, 32, 2767-2781.
20. Wiesner, C.; Nabha, S.M.; dos Santos, E.B.; Yamamoto, H.; Meng, H.; Melchior, S.W.; Bittinger, F.; Thüroff, J.W.; Vessella, R.L.; Cher, M.L., et al. c-Kit and its ligand stem cell factor: Potential contribution to prostate cancer bone metastasis. Neoplasia 2008, 10, 996-1003.
21. Cohen, P.S.; Chan, J.P.; Lipkunskaya, M.; Biedler, J.L.; Seeger, R.C. Expression of stem cell factor and c-Kit in human neuroblastoma. The Children's Cancer Group. Blood 1994, 84, 3465-3472.
22. Hassan, S.; Kinoshita, Y.; Kawanami, C.; Kishi, K.; Matsushima, Y.; Ohashi, A.; Funasaka, Y.; Okada, A.; Maekawa, T.; He-Yao, W., et al. Expression of proto-oncogene c-Kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig. Dis. Sci. 1998, 43, 8-14.
23. Hines, S.J.; Organ, C.; Kornstein, M.J.; Krystal, G.W. Co-expression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ. 1995, 6, 769-779.
24. Inoue, M.; Kyo, S.; Fujita, M.; Enomoto, T.; Kondoh, G. Co-expression of the c-Kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994, 54, 3049-3053.
25. Orfao, A.; Garcia-Montero, A.C.; Sanchez, L.; Escribano, L. Recent advances in the understanding of mastocytosis: The role of Kit mutations. Br. J. Haematol. 2007, 138, 12-30.
26. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Müller, M.; Druker, B.J.; Lydon, N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996, 56, 100-104.
27. Merchant, M.S.; Woo, C.W.; Mackall, C.L.; Thiele, C.J. Potential use of imatinib in Ewing's sarco-ma: Evidence for in vitro and in vivo activity. J. Natl. Cancer Inst. 2002, 94, 1673-1679.
28. Hodi, F.S.; Corless, C.L.; Giobbie-Hurder, A.; Fletcher, J.A.; Zhu, M.; Marino-Enriquez, A.; Friedlander, P.; Gonzalez, R.; Weber, J.S.; Gajewski, T.F., et al. Imatinib for melanomas harboring mutationally activated or amplified Kit arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol. 2013, 31, 3182-3190.
29. Ma, Y.; Zeng, S.; Metcalfe, D.D.; Akin, C.; Dimitrijevic, S.; Butterfield, J.H.; McMahon, G.; Longley, B.J. The c-Kit mutation causing human mastocytosis is resistant to STI571 and other Kit kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002, 99, 1741-1744.
30. Marech, I.; Patruno, R.; Zizzo, N.; Gadaleta, C.; Introna, M.; Zito, A.F.; Gadaleta, C.D.; Ranieri, G. Masitinib (AB1010), from canine tumor model to human clinical development: Where we are? Crit. Rev. Oncol. Hematol. 2014, 91, 98-111.
31. Yamazaki, K.; Sakamoto, M.; Ohta, T.; Kanai, Y.; Ohki, M.; Hirohashi, S. Over-expression of Kit in chromophobe renal cell carcinoma. Oncogene 2003, 22, 847-852.
32. Zigeuner, R.; Ratschek, M.; Langner, C. Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas. BJU Int. 2005, 95, 315-318.
33. Petit, A.; Castillo, M.; Santos, M.; Mellado, B.; Alcover, J.B.; Mallofré, C. Kit expression in chromophobe renal cell carcinoma: Comparative immunohistochemical analysis of Kit expression in different renal cell neoplasms. Am. J. Surg. Pathol. 2004, 28, 676-678.
34. Wang, H.Y.; Mills, S.E. Kit and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am. J. Surg. Pathol. 2005, 29, 640-646.
35. Li, G.; Gentil-Perret, A.; Lambert, C.; Genin, C.; Tostain, J. S100A1 and Kit gene expressions in common subtypes of renal tumours. Eur. J. Surg. Oncol. 2005, 31, 299-303.
36. Huo, L.; Sugimura, J.; Tretiakova, M.S.; Patton, K.T.; Gupta, R.; Popov, B.; Laskin, W.B.; Yeldandi, A.; Teh, B.T.; Yang, X.J. c-Kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum. Pathol. 2005, 36, 262-268.
37. Krüger, S.; Sotlar, K.; Kausch, I.; Horny, H.P. Expression of Kit (CD117) in renal cell carcinoma and renal oncocytoma. Oncology 2005, 68, 269-275.
38. Sengupta, S.; Cheville, J.C.; Corless, C.L.; Lohse, C.M.; Heinrich, M.C.; Kwon, E.D.; Zincke, H.; Blute, M.L.; Leibovich, B.C. Rare expression of Kit and absence of Kit mutations in high grade renal cell carcinoma. J. Urol. 2006, 175, 53-56.
39. Terada, T. Protein expression and gene mutation status of Kit and PDGFRA in renal cell carcinoma. Histol. Histopathol. 2012, 27, 297-302.
40. Shea-Donohue, T.; Stiltz, J.; Zhao, A.; Notari, L. Mast cells. Curr. Gastroenterol. Rep. 2010, 12, 349-357.
41. Irani, A.M.; Schechter, N.M.; Craing, S.S.; de Blois, G.; Schwartz, L.B. Two types of human mast cells that have distinct neutral protease composition. Proc. Natl. Acad. Sci. USA 1986, 63, 4464-4468.
42. Marshall, J.S. Mast-cell responses to pathogens. Nat. Rev. Immunol. 2004, 4, 787-799.
43. Mangia, A.; Malfettone, A.; Rossi, R.; Paradiso, A.; Ranieri, G.; Simone, G.; Resta, L. Tissue remodelling in breast cancer: Human mast cell tryptase as an initiator of myofibroblast differentiation. Histopathology 2011, 58, 1096-1106.
44. Ranieri, G.; Ammendola, M.; Patruno, R.; Celano, G.; Zito, F.A.; Montemurro, S.; Rella, A.; di Lecce, V.; Gadaleta, C.D.; de Sarro, G., et al. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int. J. Oncol. 2009, 35, 115-120.
45. Ranieri, G.; Labriola, A.; Achille, G.; Florio, G.; Zito, A.F.; Grammatica, L.; Paradiso, A. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. Int. J. Oncol. 2002, 21, 1317-1323.
46. Ranieri, G.; Roccaro, A.M.; Vacca, A.; Ribatti, D. Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: From biology to the bedside. Recent Pat. Anticancer Drug Discov. 2006, 1, 171-183.
47. Passantino, L.; Patruno, R.; Valerio, P.; Penna, A.; Mazzone, F.; Zito, A.F.; Catalano, V.; Pellecchia, A.; Jirillo, E.; Ranieri, G. Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol. Immunotoxicol. 2005, 27, 95-107.
48. Raica, M.; Cimpean, A.M.; Ceausu, R.; Ribatti, D.; Gaje, P. Interplay between mast cells and lymphatic vessels in different molecular types of breast cancer. Anticancer Res. 2013, 33, 957-963.
49. Ribatti, D.; Nico, B.; Finato, N.; Crivellato, E. Tryptase-positive mast cells and CD8-positive T cells in human endometrial cancer. Pathol. Int. 2011, 61, 442-444.
50. Nagata, M.; Shijubo, N.; Walls, A.F.; Ichimiya, S.; Abe, S.; Sato, N. Chymase-positive mast cells in small sized adenocarcinoma of the lung. Virchows Arch. 2003, 443, 565-573.
51. Horny, H.P.; Greschniok, A.; Jordan, J.H.; Menke, D.M.; Valent, P. Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: An immunohistochemical and morphometric study. J. Clin. Pathol. 2003, 56, 103-106.
52. Tomita, M.; Matsuzaki, Y.; Edagawa, M.; Shimizu, T.; Hara, M.; Sekiya, R.; Onitsuka, T. Association of mast cells with tumor angiogenesis in esophageal squamous cell carcinoma. Dis. Esophagus 2001, 14, 135-138.
53. Ribatti, D.; Guidolin, D.; Marzullo, A.; Nico, B.; Annese, T.; Benagiano, V.; Crivellato, E. Mast cells and angiogenesis in gastric carcinoma. Int. J. Exp. Pathol. 2010, 91, 350-356.
54. Ammendola, M.; Sacco, R.; Donato, G.; Zuccalà, V.; Russo, E.; Luposella, M.; Vescio, G.; Rizzuto, A.; Patruno, R.; de Sarro, G., et al. Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. Oncology 2013, 85, 111-116.
55. Acikalin, M.F.; Oner, U.; Topçu, I.; Yaşar, B.; Kiper, H.; Colak, E. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig. Liver Dis. 2005, 37, 162-169.
56. Gulubova, M.; Vlaykova, T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J. Gastroenterol. Hepatol. 2009, 24, 1265-1275.
57. Peng, S.H.; Deng, H.; Yang, J.F.; Xie, P.P.; Li, C.; Li, H.; Feng, D.Y. Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J. Gastroenterol. 2005, 11, 6521-6524.
58. Esposito, I.; Menicagli, M.; Funel, N.; Bergmann, F.; Boggi, U.; Mosca, F.; Bevilacqua, G.; Campani, D. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J. Clin. Pathol. 2004, 57, 630-636.
59. Ibaraki, T.; Muramatsu, M.; Takai, S.; Jin, D.; Maruyama, H.; Orino, T.; Katsumata, T.; Miyazaki, M. The relationship of tryptase and chymasepositive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 2005, 28, 617-621.
60. Carlini, M.J.; Dalurzo, M.C.; Lastiri, J.M.; Smith, D.E.; Vasallo, B.C.; Puricelli, L.I.; Lauría de Cidre, L.S. Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum. Pathol. 2010, 41, 697-705.
61. Ribatti, D.; Ennas, M.G.; Vacca, A.; Ferreli, F.; Nico, B.; Orru, S.; Sirigu, P. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Investig. 2003, 33, 420-425.
62. Benítez-Bribiesca, L.; Wong, A.; Utrera, D.; Castellanos, E. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J. Histochem. Cytochem. 2001, 49, 1061-1062.
63. Ranieri, G.; Patruno, R.; Lionetti, A.; di Summa, A.; Mattioli, E.; Bufo, P.; Pellecchia, A.; Ribatti, D.; Zizzo, N. Endothelial area and microvascular density in a canine non-Hodgkin's lymphoma: An interspecies model of tumor angiogenesis. Leuk. Lymphoma 2005, 46, 1639-1643.
64. Nico, B.; Mangieri, D.; Crivellato, E.; Vacca, A.; Ribatti, D. Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev. 2008, 17, 19-22.
65. Ribatti, D.; Finato, N.; Crivellato, E.; Marzullo, A.; Mangieri, D.; Nico, B.; Vacca, A.; Beltrami, C.A. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am. J. Obstet. Gynecol. 2005, 193, 1961-1965.
66. Claman, H.N. On scleroderma. Mast cells, endothelial cells, and fibroblasts. JAMA 1989, 262, 1206-1209.
67. Ehara, T.; Shigematsu, H. Mast cells in the kidney. Nephrology 2003, 8, 130-138.
68. Staemmler, M. Theodor Fahr's contribution to modern renal pathology. Medizinische 1958, 3, 897-902.
69. Lascano, E.F. Mast cells in human tumors. Cancer 1958, 11, 1110-1114.
70. Beil, W.J.; Füreder, W.; Wiener, H.; Grossschmidt, K.; Maier, U.; Schedle, A.; Bankl, H.C.; Lechner, K.; Valent, P. Phenotypic and functional characterization of mast cells derived from renal tumor tissues. Exp. Hematol. 1998, 26, 158-169.
71. Tuna, B.; Yorukoglu, K.; Unlu, M.; Mungan, M.U.; Kirkali, Z. Association of mast cells with microvessel density in renal cell carcinomas. Eur. Urol. 2006, 50, 530-534.
72. Mohseni, M.G.; Mohammadi, A.; Heshmat, A.S.; Kosari, F.; Meysamie, A.P. The lack of correlation between mast cells and microvessel density with pathologic feature of renal cell carcinoma. Int. Urol. Nephrol. 2010, 42, 109-112.
73. Yoshino, S.; Kato, M.; Okada, K. Evaluation of the prognostic significance of microvessel count and tumor size in renal cell carcinoma. Int. J. Urol. 1998, 5, 119-123.
74. Nativ, O.; Sabo, E.; Reiss, A.; Wald, M.; Madjar, S.; Moskovitz, B. Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology 1998, 51, 693-696.
75. MacLennan, G.T.; Bostwick, D.G. Microvessel density in renal cell carcinoma: Lack of prognostic significance. Urology 1995, 46, 27-30.
76. Kirkali, Z.; Yorukoglu, K.; Ozkara, E.; Kazimoglu, H.; Mungan, U. Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma. Int. J. Urol. 2001, 8, 697-703.
77. Patruno, R.; Marech, I.; Zizzo, N.; Ammendola, M.; Nardulli, P.; Gadaleta, C.; Introna, M.; Capriuolo, G.; Rubini, R.A.; Ribatti, D., et al. c-Kit expression, angiogenesis, and grading in canine mast cell tumour: A unique model to study c-Kit driven human malignancies. Biomed. Res. Int. 2014, doi:10.1155/2014/730246.
78. Vuky, J.; Isacson, C.; Fotoohi, M.; dela Cruz, J.; Otero, H.; Picozzi, V.; Malpass, T.; Aboulafia, D.; Jacobs, A. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Investig. New Drugs 2006, 24, 85-88.
79. Calvani, N.; Morelli, F.; Chiuri, V.; Gnoni, A.; Scavelli, C.; Fedele, P.; Orlando, L.; Maiello, E.; Lorusso, V.; Cinieri, S. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: Are the two options alike? Med. Oncol. 2013, 30, 578.